Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility.

Journal of acquired immune deficiency syndromes (1999) - 15 Dec 2006

Ross Lisa L, Parkin Neil, Gerondelis Peter, Chappey Colombe, Underwood Mark R, St Clair Marty H, Lanier Ernest R

Abstract excerpt

The impact of drug resistance-associated mutations on subsequent antiretroviral therapy is an important consideration in managing treatment-experienced, HIV-1-infected patients. Lamivudine (3TC) and emtricitabine (FTC) are structurally related nucleoside reverse transcriptase inhibitors (NRTIs) approved for use in HIV-1-infected individuals. To evaluate whether susceptibility differences exist between lamivudine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV-1
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Drug Resistance, Viral

Share to Emtricitabine

Share to Lamivudine

Share to Mutation

Share to Thymidine

Source

Identifiers

PMID: 17075395
DOI: 10.1097/01.qai.0000243123.90400.62

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility.PMID 17075395Read ↗

A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.Semantic proximity Read ↗

Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.Semantic proximity Read ↗

Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.Semantic proximity Read ↗

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir AlafenamideSemantic proximity Read ↗

Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.Semantic proximity Read ↗

Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.Semantic proximity Read ↗

Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing RegimensSemantic proximity Read ↗

Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.Semantic proximity Read ↗

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.Semantic proximity Read ↗

Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.Semantic proximity Read ↗

Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.Semantic proximity Read ↗

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.